Effects of REMS deprivation on striatal dopamine and acetylcholine in rats.

Changes in the concentration of striatal dopamine (DA) and acetylcholine (ACh) in rats deprived of REM sleep for 10 days were compared with those obtained after a 4 day deprivation procedure. Animals placed on small (7 cm dia.) islands surrounded by water were completely deprived of REM sleep but able to obtain some slow-wave sleep. Concentration of striatal DA was significantly increased after 4 days and 10 days of REM sleep deprivation by 73 and 133%, respectively when compared to controls. Levels of ACh in the striatum were significantly enhanced (by 28%) after 10 day, but failed to show significant change after 4 day REM sleep deprivation procedure. The short term locomotor activity was significantly higher in REM sleep-deprived animals. Our data indicate that REM sleep deprivation results in marked alterations of both cholinergic and dopaminergic mechanisms in the rat striatum.     

Effects of morphine on striatal dopamine metabolism: Possible mechanism of its opposite effect on locomotor activity in rats and mice

In rats, the catalepsy induced by analgesic doses of morphine was paralleled by a dose-dependent increase in the concentration of dopamine's (DA) metabolite, homovanillic acid (HVA) in the striatum. The effect of morphine on striatal HVA was supra-additive with the corresponding action of chlorpromazine (CPZ). It is concluded that in rats morphine induces catalepsy and a decrease in dopaminergic activity in the striatum by a mechanism different from that of other cataleptogenic agents, such as the neurologic CPZ. In mice, morphine induced an increased in locomotor activity (running); this effect was attenuated by bilateral lesions placed in the caudate nucleus. Pretreatment of mice with diethyldithiocarbamate (DDC), or d,l-α-methyl-p-tyrosine (αMT), inhibited the morphine-induced running activity. In αMT-treated mice 1-3,4-dihydroxyphenylalanine (l-dopa) restored the effectiveness of morphine whereas d,l-threo-3,4-dihydroxyphenylserine (dops) was ineffective. In contrast, in DDC-treated mice, dops and clonidine, but not 1-dopa, were effective in restoring morphine's effectiveness. Doses of morphine inducing running activity in mice produced a slight increase in striatal HVA level. It is concluded that in mice morphine produces locomotor hyperactivity by releasing DA from the presynaptic terminals in the striatum, thus increasing the dopaminergic activity in this structure. Norepinephrine has an important auxiliary function.     

Changes in striatal dopamine metabolism during precipitated morphine withdrawal

Precipitation of withdrawal in morphine tolerant/dependent rats by either naloxone or the partial agonist ZK 48491 caused a significant increase in the contration of striatal DA, which persisted for at least 1 h. During the same time the probenecid-induced accumulation of HVA and DOPAC was reduced in the striatum in relation to probenecid-treated tolerant/dependent controls. 20 min after precipitation of withdrawal by naloxone, the striatal concentration of 3-methoxytyramine was decreased by about 40%, while the activity of the DA metabolizing enzymes, MAO and COMT, remained unchanged. Naloxone-precipitated withdrawal was, further, found to delay the depletion of striatal DA caused by inhibition of synthesis 90 min after alpha-methyl-p-tyrosine treatment. All these results provide evidence for a decreased release of DA from the striatum during precipitated morphine withdrawal.     

Alterations in striatal acetylcholine overflow by cocaine,morphine, and MK-801: relationship to locomotor output

The activity of cholinergic interneurons in the striatum appears to be modulated by a variety of different systems including dopamine, opiate, and glutamate. The purpose of this study was to characterize the effects of drugs known to act on these three systems (i.e., cocaine, morphine, and MK-801) on striatal ACh overflow with microdialysis procedures, and to determine if alterations in ACh function induced by these agents are related to changes in locomotor activity. Cocaine was found to increase striatal ACh following intraperitoneal injections of 20 and 40 mg/kg, but not 10 mg/kg. The increases in locomotor activity induced by cocaine appeared to be dose dependent, while the effects on striatal ACh were not. Injections of 0.1 mg/kg MK-801 (a non-competitive NMDA receptor antagonist) produced dramatic increases in locomotor activity while decreasing striatal ACh overflow. A lower dose (0.03 mg/kg) of MK-801 failed to alter locomotor activity or striatal ACh. Morphine produced an apparent dose-dependent elevation in striatal ACh while only the lowest dose (5 mg/kg) increased locomotor activity. These appears to be no relationship between alterations in striatal ACh and locomotor output following systemic administration of these psychoactive agents.     

Lethality of tyrosine in mice

Summary The activity of the striatal dopamine system during preciptiated morphine withdrawal was studied in rats using a model in which the striatum was unilaterally inactivated by the local injection of KCl. In naive rats dopamine agonists administered just prior to KCl induced ipsilateral, turning or circling, while dopamine antagonists in the same situation caused contralateral turning.Withdrawal precipitated by morphine antagonists in rats made dependent by repeated implantation of morphine pellets induced contralateral circling during unilateral inactivation of the striatum. This contralateral circling was only slightly enhanced by haloperidol, but strongly enhanced by a low dosage of apomorphine as well as by some weak dopamine agonists such as CB 154 or By 101. However, high doses of apomorphine completely reversed the withdrawal-induced contralateral circling into ipsilateral circling. Other dopamine agonists, such as d-amphetamine, l-Dopa and piribedil, did not abolish the withdrawal-induced contralateral circling, however, they caused the appearance of an additional ipsilateral circling. Other types of drugs which are known to intensify withdrawal-induced jumping (desipramine, atropine, caffeine) enhanced contralateral circling. There are also other parallels between jumping and contralateral circling induced by withdrawal.The direction of naloxone-induced asymmetric behaviour during acute unilateral inactivation of the striatum suggests that striatal dopaminergic activity is reduced during precipitated withdrawal; the other results reported point to the possibility that extrastriatal dopaminergic mechanisms or different dopamine receptor types within the striatum are involved.     

Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum

The involvement of heterogeneous dopamine (DA) receptors in the regulation of striatal cholinergic neurotransmission was investigated by measuring the release of acetylcholine (ACh) from isolated striatum of the rat. The DA agonists apomorphine (3.7 X 10(-7)-7.4 X 10(-4) mol/l) and piribedil (3.3 X 10(-6)-9.9 X 10(-5) mol/l) exerted a biphasic action: in low concentrations they enhanced, while in high concentrations they inhibited, the ouabain-induced release of ACh. The enhancement of ACh release elicited by low concentrations of DA agonists was reversed by a noncataleptogenic dose of pimozide. 6-hydroxydopamine (6-OHDA) pretreatment also prevented the stimulatory action of apomorphine or piribedil on ACh release. In 6-OHDA pretreated striatum, apomorphine caused a biphasic inhibition of ACh release in a concentration dependent manner. DPI (3,4-dihydroxyphenylamino/-2-imidazoline, 2.5 X 10(-5)-2.5 X 10(-4) mol/l) increased the release of ACh in a monophasic manner and did not induce inhibition of transmitter output in 6-OHDA pretreated striatum. Pretreatment of rats with increasing doses of haloperidol or pimozide (0.037-15 mg/kg) exerted a biphasic action on striatal ACh release; low doses decreased and high doses enhanced the transmitter output and the elevation was accompanied by the appearance of catalepsy. From these experiments it is concluded that multiple DA receptors are involved in the regulation of striatal cholinergic neurotransmission. Among these, the presynaptic DA autoreceptors located on nigrostriatal nerve endings are the most sensitive to both agonists and antagonists. DA receptors located on cholinergic interneurons of the striatum, which are postsynaptic in relation to nigrostriatal neurons, possess high and low affinity to apomorphine. Stimulation of DA autoreceptors enhances, while that of postsynaptic DA receptors leads to inhibition of ACh release.     

Cocaine releases limbic acetylcholine through endogenous dopamine action on D1 receptors.

Cocaine (10 and 20 mg/kg i.p.) enhanced the extracellular concentration of acetylcholine (ACh) in the ventral striatum of freely moving rats. The enhancement was prevented both by dopamine (DA) D1 receptor blockade with SCH 23390 (0.1 mg/kg s.c.) and by depletion of endogenous DA after coadministration of reserpine (5 mg/kg i.p.) and alpha-methyltyrosine (alpha-MT) (150 mg/kg i.p.). In contrast, blockade of DA D2 receptors with (-)-sulpiride (20 mg/kg i.p.) did not prevent the cocaine-induced increase in ACh release. These results indicate that the cocaine-induced stimulation of ACh release is mediated by an action of DA on D1 receptors, and suggest that the enhancement of ACh release might play a functional role in the central effects of cocaine. Moreover, DA depletion after reserpine + alpha-MT or D1 receptor blockade with SCH 23390 led to a comparable decrease of baseline ACh release, suggesting that striatal cholinergic interneurons are under D1 receptor-mediated facilitatory dopaminergic control.     

Involvement of opioid mu1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission.

The role of mu1-opioid receptors in the acceleration of cerebral dopaminergic transmission induced by morphine and the putative mu1-opioid agonist, etonitazene, was studied in rats by measuring the tissue levels of dopamine (DA) and its metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the dorsal striatum and nucleus accumbens. The striatal extracellular concentrations of DA and its metabolites in freely moving rats were estimated as well. Morphine (3 mg/kg) and etonitazene (2.5 microg/kg) increased the striatal and accumbal dopamine metabolism as measured by the tissue ratios of DOPAC/DA and HVA/DA. The mu1-opioid receptor antagonist, naloxonazine (15 mg/kg), significantly antagonized these elevations except the morphine-induced elevation of striatal HVA/DA ratio. Both morphine (3 mg/kg) and etonitazene (1, 2.5, and 5 microg/kg) elevated the striatal extracellular DA, DOPAC, and HVA. Naloxonazine antagonized the effects of morphine and etonitazene on striatal extracellular DA concentration as well as etonitazene's effects on DOPAC and HVA, but not morphine's effects on DOPAC and HVA. As we previously showed concerning morphine, the conditioned place preference induced by etonitazene was inhibited by naloxonazine. These findings emphasize the role of mu1-opioid receptors in opioid reward, in which the mesolimbic dopaminergic system is considered to be importantly involved. Our results clearly show that in addition to the mesolimbic dopaminergic system the mu1-opioid receptors are also involved in the control of nigrostriatal DA release and metabolism. However, the effects of etonitazene on the striatal DA differ from those of morphine, suggesting that the opioid mechanisms regulating these two DA systems differ.     

Evidence for a possible dopaminergic link in the action of acetylcholine in the rat substantia nigra

The activity of the rat nigro-striatal dopaminergic system has been studied after unilateral injections of hemicholinium-3[HC-3] or carbachol into the substantia nigra zona reticulata. HC-3 produced intense contralateral turning which was antagonized by haloperidol. The dopamine (DA) concentration was reduced and the homovanillic acid (HVA) concentration was increased in the ipsilateral striatum, indicating that removal of the effect of acetylcholine (ACh) from the nigra leads to activation of the nigro-striatal DA pathway. Conversely carbachol produced ipsilateral circling with increased DA concentration and reduced HVA concentration in the ipsilateral striatum. The action of carbachol was antagonized if α-flupenthixol (α-FP) but not β-flupenthixol (β-FP) was added to the carbachol injection solution. This observation suggests that the action of ACh may be mediated by way of an inhibitory DA system. A tentative hypothesis is proposed to explain these observations.     

Reactivity to amphetamine in perinatally undernourished rats: behavioral and neurochemical correlates

Adult rats deprived at perinatal age and then rehabilitated on balanced chow were treated with a multiple amphetamine (AMPH) schedule (2 mg/kg/48 hr) and submitted, on days of injections, to an open-field test. Throughout 11 sessions, deprived rats showed a progressive increase of locomotor activity as compared with controls. Stereotyped activity evaluated during the AMPH treatment did not differ between control and deprived animals. No differences were detected in basal values of the dopaminergic function measured in naive control and deprived animals. By the end of the multiple AMPH treatment, a reduction of striatal DA and DOPAC levels together with a lower apparent DA turnover rate was detected in deprived animals. Besides, DA receptor binding was significantly increased in striatum from deprived rats as compared with controls. These results demonstrate that a repeated AMPH treatment, that was unable to alter the normal behavior of control rats, produced in early undernourished animals a progressive sensitization to AMPH effects, in addition to significant changes in the striatal dopaminergic function.     

Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats

Summary To clarify the effects of withdrawal from chronic morphine treatment on cerebral dopamine (DA) turnover, we have measured the -methyl-p-tyrosine (MT)-induced depletion of DA in five brain areas of male Wistar rats given morphine twice daily for 40 or 60 days. After the last morphine dose (50 or 70 mg/kg) the rats were withdrawn for 1, 2 or 4 days. In order to study the development of tolerance some of the rats were challenged with 10 mg/kg of morphine.Withdrawal of morphine retarded the MT-induced DA depletion in the limbic forebrain and after long enough chronic treatment in the striatum, too. The challenge dose of morphine accelerated the cerebral DA depletion slightly less in rats withdrawn for 1 day from 60-day chronic morphine treatment than in rats treated chronically with saline, but it enhanced the DA depletion more in rats withdrawn from morphine for 2 and 4 days than in chronic saline rats. This enhancement was clearest in rats withdrawn for 4 days from 60-day treatment. Thus withdrawal from morphine seems to sensitize the rats to the DA depletion accelerating effect of morphine.Our results show that repeated administration of morphine creates no marked tolerance to the DA depletion accelerating effect of morphine. In contrast, the dopaminergic neurones of the chronically treated rats seem to depend on continuous morphine administration for their normal functioning. Furthermore, the retarded DA turnover after discontinuation of morphine treatment seems to sensitize the dopaminergic neurones to the DA depletion accelerating effect of morphine. The limbic dopaminergic neurones are more easily affected by both acute and chronic morphine treatment than the striatal ones.     

Effects of morphine on release of acetylcholine in the rat striatum: an in vivo microdialysis study

Summary We examined the effect of morphine on the release of acetylcholine (ACh) in the striatum of freely moving rats using the in vivo microdialysis method. The basal level of ACh was 3.01 ± 0.51 pmol/30 l/15 min in the presence of neostigmine (10 M). Tetrodotoxin (1 M), a selective blocker of voltage-dependent Na⁺ channels, rapidly decreased the release of ACh in the striatal perfusates. Morphine at a dose of 10 mg/kg (i.p.) caused a reduction of ACh release in the striatum at 90–150 min. However, a lower dose of morphine (5 mg/kg, i.p.) did not affect ACh release in the striatum. The reduction following intraperitoneal administration of morphine was abolished by naloxone (1.0 mg/kg).After microinjection of the neurotoxin 6-hydroxydopamine (6 g/3 l, 7 days before) in the substantia nigra, the morphine (10 mg/kg)-induced decrease of ACh was attenuated, and a similar result occurred following reserpine (2 mg/kg, i.p.) 24 h before combined with -methyl-p-tyrosine (300 mg/kg, i. p.) 2.5 h before.These findings indicate that morphine exerts an inhibitory influence on striatal ACh release in freely moving rats and that this inhibitory effect is mediated by the nigro-striatal dopaminergic system.Correspondence to K. Taguchi at the above address     

Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: II. Effects on extracellular monoamine,acetylcholine and adenosine levels monitored with in vivo microdialysis

6-hydroxydopamine (6-OHDA, 100 µg in 5 µl) was injected into the right ventricle of 3-day-old Sprague-Dawley rats in order to produce a unilateral dopamine (DA) lesion. At adult stage, the rats were implanted with microdialysis probes into the left and right striata. On the injected side, basal extracellular levels of DA were reduced by >65%, as compared to the contralateral side or to the levels found in vehicle-injected rats. Extracellular 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were reduced by >95%, while acetylcholine (ACh) was decreased by >50%.d-Amphetamine (2 mg/kg SC) produced a 10-fold increase in extracellular DA levels in the striatum contralateral to the 6-OHDA-injected side, while on the ipsilateral side, DA levels were not affected byd-amphetamine.d-Amphetamine produced an increase (>2 fold) in extracellular ACh levels, on both ipsilateral and contralateral sides. Choline and adenosine levels were unaffected by any of the experimental conditions. Thus, neonatal unilateral ICV administration of 6-OHDA produced an ipsilateral decrease in striatal extracellular DA, DOPAC and HVA levels, compared to the contralateral side. A reduction of extracellular ACh levels was also observed on the 6-OHDA-injected side. The DA releasing effect ofd-amphetamine was abolished on the 6-OHDA-injected side, but not that on ACh levels, indicating that striatal DA and AChd-amphetamine-induced release are produced by independent mechanisms in the meonatally unilateral 6-OHDA-treated animals. As a whole the present study gives evidence showing that neonatal unilateral ICV treatment with 6-OHDA produces a predominantly unilateral lesion of the mesencephalic DA systems.     

Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: participation of imidazoline and norepinephrine receptors.

The alpha2 adrenoceptor (alpha2R) agonist clonidine is used as a treatment for heroin addiction. Substantial evidence indicates that dopaminergic and noradrenergic systems have key roles in opiate dependence and withdrawal but the possible interactions between these two pathways remain unclear. The objective of this study was to establish the effects of clonidine pretreatment on ventral tegmental area dopaminergic (VTA DA) neuronal activity during morphine withdrawal. Responses of VTA DA neurons to withdrawal precipitated by naltrexone were characterized in anesthetized rats using extracellular recordings. As expected, withdrawal produced a marked inhibition of VTA DA neuronal activity. However, pretreatment with clonidine prevented this inhibition induced by withdrawal, and instead produced a long-lasting activation of firing rate (+50%) and burst firing (+19%). In contrast, pretreatment with a more selective alpha2R agonist, UK14304, did not prevent the inhibition of VTA DA neuron activity during withdrawal. We tested whether the high affinity of clonidine for imidazoline-1 receptors (I1Rs) was responsible for the difference between these two alpha2R agonists. In morphine-dependent rats pretreated with rilmenidine (mixed alpha2R/I1R agonist), precipitation of withdrawal elicited a 22% increase of VTA DA impulse activity. The action of clonidine on I1Rs was studied by coadministering clonidine with RX821002, a specific alpha2R antagonist. Pretreatment with RX821002 plus clonidine prevented the inhibition of VTA DA activity during withdrawal but failed to produce excitation. These results indicate that the pharmacological effects of clonidine on VTA DA neurons during morphine withdrawal is related to actions on I1Rs as well as alpha2Rs.     

Naloxone-precipitated changes in biogenic amines and their metabolites in various brain regions of butorphanol-dependent rats

Influence of a naloxone (an opioid receptor antagonist) challenge (5 mg/kg, IP) on levels of biogenic amines and their metabolites in various brain regions of rats infused continuously with butorphanol (a μ/δ/κ mixed opioid receptor agonist; 26 nmol/μl/h) or morphine (a μ-opioid receptor agonist; 26 nmol/μl/h) was investigated using highperformance liquid chromatography with electrochemical detection (HPLC-ED). Naloxone precipitated a withdrawal syndrome and decreased the levels of: dopamine (DA) in the cortex and striatum, 3,4-dihydroxyphenylacetic acid (DOPAC) in the striatum, homovanilic acid (HVA) in the striatum, limbic, midbrain, and pons/medulla regions in butorphanol-dependent rats. However, the levels of norepinephrine (NE), serotonin (5-hydroxytryptamine; 5-HT), and 5-hydroxyindoleacetic acid (5-HIAA) in the regions studied were not affected by naloxone-precipitated withdrawal. In addition, naloxone increased the HVA/DA ratio in the cortex, while this ratio was reduced in the limbic, midbrain, and pons/medulla. The reduction of 5-HIAA/5-HT ratio was also detected in the limbic area. In the animals rendered dependent on morphine, the results obtained were similar to those of butorphanol-dependent rats except for changes of 5-HIAA levels in some brain regions. These results suggest that an alteration of dopaminergic neuron activity following a reduction of DA and its metabolites in specific brain regions (e.g., striatum, limbic, midbrain, and pons/medulla) play an important role in the expression of the opioid withdrawal syndrome.     

Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study

 Previously, only in vitro studies have shown that chronic administration of morphine provokes long-lasting enhanced activity of accumbal cholinergic neurons, which may contribute to the behavioural sensitization, positive reinforcement and aversive effects associated with enhanced drug-seeking. The present study was aimed at clarifying whether these adaptive changes would also be supported by in vivo microdialysis measurements in freely moving rats, distinguishing between the accumbal substructures shell and core, and observing behavioural changes simultaneously. Acute administration of morphine dose-dependently decreased acetylcholine (ACh) release in the nucleus accumbens (NAc), with 10 mg/kg SC being most effective, 5 mg/kg ineffective. On day 5 of spontaneous abstinence from chronic morphine treatment (10–40 mg/kg morphine dose once daily for 5 days), when withdrawal symptoms were still present, even a lower morphine dose (5 mg/kg) was effective in decreasing ACh release in the NAc. During the later phase of abstinence, when no withdrawal symptoms were detectable, the opposite effect, i.e. an increase of ACh release was found. This later effect may represent a long-lasting neuroadaptive effect of morphine. These adaptive effects seemed to be more prominent in the NAc shell. Concurrent with these changes in ACh release, morphine challenges produced marked behavioural stereotypes, possibly indicating behavioural sensitization. Received: 7 April 1998 / Final version: 23 July 1998     

Acute effects of morphine on dopamine synthesis and release and tyrosine metabolism in the rat striatum

The effect of the acute administration of morphine (60 mg/kg) on the metabolism of dopamine (DA) and tyrosine in the rat striatum were investigated using in vivo and in vitro methods. 30 min after morphine injection, the initial accumulation of ³H-DA in tissues seen after the i.v. injection of L-3,5-H-tyrosine was enhanced as well as the accumulation of ³HH₂O and ³H-DA in tissues and medium of striatal slices incubated with the ³H precursor. These results and the estimation of the conversion index of tyrosine into DA (³H-DA/tyrosine specific activity) indicated that morphine stimulated DA synthesis. This effect was not seen 2 hr later. The enhanced DA synthesis was associated with a parallel increase in the release of newly synthesized ³H-DA as indicated by the greater accumulation of ³H-DA in incubating medium of slices of morphine-pretreated rats. Therefore the increased endogenous levels of DA seen after morphine are related to the increased synthesis of the transmitter. Apart from its effect on dopaminergic neuron activity, morphine also induced marked changes in tyrosine metabolism, particularly at 2 or 2.5 hr after its injection. Tyrosine levels in plasma and in striatum were about 160% of the control levels at this time: these changes in the size of the precursor pool may explain the enhanced accumulation of ³H-tyrosine seen in plasma and striatum 10 min after the ³H-amino acid injection. Marked changes in endogenous levels of DA and tyrosine occurred in the striatum of control animals from 9.00 to 12.00 am. Acute treatment with morphine significantly affected these diurnal variations.     

On the Origin of Cortical Dopamine: Is it a Co-Transmitter in Noradrenergic Neurons?

Dopamine (DA) and noradrenaline (NA) in the prefrontal cortex (PFC) modulate superior cognitive functions, and are involved in the aetiology of depressive and psychotic symptoms. Moreover, microdialysis studies in rats have shown how pharmacological treatments that induce modifications of extracellular NA in the medial PFC (mPFC), also produce parallel changes in extracellular DA.To explain the coupling of NA and DA changes, this article reviews the evidence supporting the hypothesis that extracellular DA in the cerebral cortex originates not only from dopaminergic terminals but also from noradrenergic ones, where it acts both as precursor for NA and as a co-transmitter.Accordingly, extracellular DA concentration in the occipital, parietal and cerebellar cortex was found to be much higher than expected in view of the scarce dopaminergic innervation in these areas.Systemic administration or intra-cortical perfusion of alpha(2)-adrenoceptor agonists and antagonists, consistent with their action on noradrenergic neuronal activity, produced concomitant changes not only in extracellular NA but also in DA in the mPFC, occipital and parietal cortex.Chemical modulation of the locus coeruleus by locally applied carbachol, kainate, NMDA or clonidine modified both NA and DA in the mPFC.Electrical stimulation of the locus coeruleus led to an increased efflux of both NA and DA in mPFC, parietal and occipital cortex, while in the striatum, NA efflux alone was enhanced.Atypical antipsychotics, such as clozapine and olanzapine, or antidepressants, including mirtazapine and mianserine, have been found to increase both NA and DA throughout the cerebral cortex, likely through blockade of alpha(2)-adrenoceptors. On the other hand, drugs selectively acting on dopaminergic transmission produced modest changes in extracellular DA in mPFC, and had no effect on the occipital or parietal cortex.Acute administration of morphine did not increase DA levels in the PFC (where NA is diminished), in contrast with augmented dopaminergic neuronal activity; moreover, during morphine withdrawal both DA and NA levels increased, in spite of a diminished dopaminergic activity, both increases being antagonised by clonidine but not quinpirole administration.Extensive 6-hydroxy dopamine lesion of the ventral tegmental area (VTA) decreases below 95% of control both intra- and extracellular DA and DOPAC in the nucleus accumbens, but only partially or not significantly in the mPFC and parietal cortex.The above evidence points to a common origin for NA and DA in the cerebral cortex and suggests the possible utility of noradrenergic system modulation as a target for drugs with potential clinical efficacy on cognitive functions.     

Brain acetylcholine in morphine pellet implanted rats given naloxone

Adult male rats were implanted with intraventricular (ivt.) brain cannulae for injection of 5 g of acetylseco-hemicholinium-3 (acetylseco HC-3) as a means of studying acetylcholine (ACh) utilization during morphine withdrawal. Animals were made dependent by implanting s.c. two 75 mg morphine base pellets 24 hrs apart. On the 4th day animals were given 10 mg/kg of naloxone i.p. and/or 5 g acetylseco HC-3 ivt. and sacrificed by decapitation at various times. The brains were removed and assayed for ACh using a pyrolysis gas Chromatographie procedure. Total brain ACh before or after acetylseco-HC-3 was not altered at 5, 30, 60 and 120 but was decreased at 10 min after naloxone. These results are in sharp contrast to our previous data of enhanced brain ACh utilization in withdrawn rats made dependent to morphine by several weeks of twice daily injections. It is apparent that short term morphine pellet administration does not produce the marked neurochemical and behavioral changes of long term morphine injections.Supported in part by grant DA 00830, USPHS.     

Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats

The effects of agmatine on morphine-induced locomotion sensitization and morphine-induced changes in extracellular striatal dopamine (DA) and DA metabolites were studied. The locomotor response to morphine challenge (3 mg/kg, s.c.) was enhanced in rats 3 days after repeated morphine administration, indicating development of locomotion sensitization. In vivo microdialysis demonstrated a significant increase in striatal basal levels of the DA metabolites DOPAC and HVA, but not in DA itself, and an increase in DA response to morphine challenge in rats 3 days after withdrawal. Agmatine (1, 10, 80 mg/kg) inhibited morphine-induced locomotion sensitization and the changes in DA noted above. Idazoxan attenuated the effects of agmatine on locomotion, suggesting that the effects are mediated by imidazoline receptors. In addition, repeated morphine also increased the expression of tyrosine hydroxylase mRNA in the VTA after 4 days of morphine pretreatment, while decreasing the expression of dynorphin mRNA at 3 days after withdrawal. Agmatine inhibited morphine-induced changes in dynorphin, but not in tyrosine hydroxylase mRNA expression. These data suggest that agmatine, likely by activating imidazoline receptors, inhibits morphine-induced locomotion sensitization and morphine-induced changes in extracellular DA and in dynorphin expression. Thus, agmatine deserves further study as an anti-opioid medication.